Active Ingredient History

NOW
  • Now
Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October¬†2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.   Wikipedia

More Chemistry
cs-1008 | tigatuzumab | tra-8

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue